nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—AOX1—Methotrexate—systemic scleroderma	0.209	0.609	CbGbCtD
Zaleplon—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0789	0.23	CbGbCtD
Zaleplon—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0308	0.0896	CbGbCtD
Zaleplon—CYP3A4—Prednisone—systemic scleroderma	0.0246	0.0716	CbGbCtD
Zaleplon—Osteoarthritis—Methotrexate—systemic scleroderma	0.000371	0.000566	CcSEcCtD
Zaleplon—Confusional state—Lisinopril—systemic scleroderma	0.000371	0.000565	CcSEcCtD
Zaleplon—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000371	0.000565	CcSEcCtD
Zaleplon—Headache—Mometasone—systemic scleroderma	0.00037	0.000564	CcSEcCtD
Zaleplon—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00037	0.000564	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00037	0.000563	CcSEcCtD
Zaleplon—Insomnia—Mycophenolic acid—systemic scleroderma	0.000369	0.000563	CcSEcCtD
Zaleplon—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000368	0.00056	CcSEcCtD
Zaleplon—Oedema—Lisinopril—systemic scleroderma	0.000368	0.00056	CcSEcCtD
Zaleplon—Pruritus—Captopril—systemic scleroderma	0.000367	0.00056	CcSEcCtD
Zaleplon—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000367	0.000559	CcSEcCtD
Zaleplon—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000366	0.000558	CcSEcCtD
Zaleplon—Pain—Leflunomide—systemic scleroderma	0.000366	0.000558	CcSEcCtD
Zaleplon—Constipation—Leflunomide—systemic scleroderma	0.000366	0.000558	CcSEcCtD
Zaleplon—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000365	0.000556	CcSEcCtD
Zaleplon—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000364	0.000555	CcSEcCtD
Zaleplon—Somnolence—Mycophenolic acid—systemic scleroderma	0.000363	0.000553	CcSEcCtD
Zaleplon—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000363	0.000553	CcSEcCtD
Zaleplon—Shock—Lisinopril—systemic scleroderma	0.000362	0.000551	CcSEcCtD
Zaleplon—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000361	0.00055	CcSEcCtD
Zaleplon—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000359	0.000548	CcSEcCtD
Zaleplon—Tachycardia—Lisinopril—systemic scleroderma	0.000359	0.000547	CcSEcCtD
Zaleplon—Abdominal pain—Azathioprine—systemic scleroderma	0.000358	0.000546	CcSEcCtD
Zaleplon—Body temperature increased—Azathioprine—systemic scleroderma	0.000358	0.000546	CcSEcCtD
Zaleplon—Skin disorder—Lisinopril—systemic scleroderma	0.000357	0.000544	CcSEcCtD
Zaleplon—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000356	0.000542	CcSEcCtD
Zaleplon—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000356	0.000542	CcSEcCtD
Zaleplon—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000355	0.000541	CcSEcCtD
Zaleplon—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000355	0.00054	CcSEcCtD
Zaleplon—Irritability—Methotrexate—systemic scleroderma	0.000355	0.00054	CcSEcCtD
Zaleplon—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000354	0.000539	CcSEcCtD
Zaleplon—Erectile dysfunction—Prednisone—systemic scleroderma	0.000354	0.000539	CcSEcCtD
Zaleplon—Feeling abnormal—Leflunomide—systemic scleroderma	0.000353	0.000537	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000353	0.000537	CcSEcCtD
Zaleplon—Mood swings—Methotrexate—systemic scleroderma	0.000352	0.000536	CcSEcCtD
Zaleplon—Nausea—Mometasone—systemic scleroderma	0.000351	0.000535	CcSEcCtD
Zaleplon—Anorexia—Lisinopril—systemic scleroderma	0.000351	0.000534	CcSEcCtD
Zaleplon—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00035	0.000533	CcSEcCtD
Zaleplon—Weight increased—Prednisone—systemic scleroderma	0.00035	0.000533	CcSEcCtD
Zaleplon—Ataxia—Methotrexate—systemic scleroderma	0.000349	0.000532	CcSEcCtD
Zaleplon—Pain—Mycophenolic acid—systemic scleroderma	0.000349	0.000532	CcSEcCtD
Zaleplon—Constipation—Mycophenolic acid—systemic scleroderma	0.000349	0.000532	CcSEcCtD
Zaleplon—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000532	CcSEcCtD
Zaleplon—Weight decreased—Prednisone—systemic scleroderma	0.000348	0.000529	CcSEcCtD
Zaleplon—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000347	0.000529	CcSEcCtD
Zaleplon—Hyperglycaemia—Prednisone—systemic scleroderma	0.000347	0.000528	CcSEcCtD
Zaleplon—Hypotension—Lisinopril—systemic scleroderma	0.000344	0.000524	CcSEcCtD
Zaleplon—Dizziness—Captopril—systemic scleroderma	0.000343	0.000523	CcSEcCtD
Zaleplon—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000343	0.000522	CcSEcCtD
Zaleplon—Depression—Prednisone—systemic scleroderma	0.000342	0.00052	CcSEcCtD
Zaleplon—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000519	CcSEcCtD
Zaleplon—Urticaria—Leflunomide—systemic scleroderma	0.00034	0.000518	CcSEcCtD
Zaleplon—Abdominal pain—Leflunomide—systemic scleroderma	0.000338	0.000515	CcSEcCtD
Zaleplon—Body temperature increased—Leflunomide—systemic scleroderma	0.000338	0.000515	CcSEcCtD
Zaleplon—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000336	0.000513	CcSEcCtD
Zaleplon—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000512	CcSEcCtD
Zaleplon—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000512	CcSEcCtD
Zaleplon—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000512	CcSEcCtD
Zaleplon—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000336	0.000511	CcSEcCtD
Zaleplon—Breast disorder—Methotrexate—systemic scleroderma	0.000336	0.000511	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000335	0.00051	CcSEcCtD
Zaleplon—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000335	0.00051	CcSEcCtD
Zaleplon—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000334	0.000509	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000334	0.000509	CcSEcCtD
Zaleplon—Insomnia—Lisinopril—systemic scleroderma	0.000333	0.000507	CcSEcCtD
Zaleplon—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000332	0.000506	CcSEcCtD
Zaleplon—Paraesthesia—Lisinopril—systemic scleroderma	0.00033	0.000503	CcSEcCtD
Zaleplon—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000329	0.000501	CcSEcCtD
Zaleplon—Dyspnoea—Lisinopril—systemic scleroderma	0.000328	0.000499	CcSEcCtD
Zaleplon—Rash—Captopril—systemic scleroderma	0.000327	0.000499	CcSEcCtD
Zaleplon—Dermatitis—Captopril—systemic scleroderma	0.000327	0.000498	CcSEcCtD
Zaleplon—Somnolence—Lisinopril—systemic scleroderma	0.000327	0.000498	CcSEcCtD
Zaleplon—Headache—Captopril—systemic scleroderma	0.000325	0.000496	CcSEcCtD
Zaleplon—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000495	CcSEcCtD
Zaleplon—Dyspepsia—Lisinopril—systemic scleroderma	0.000324	0.000493	CcSEcCtD
Zaleplon—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000323	0.000492	CcSEcCtD
Zaleplon—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000323	0.000492	CcSEcCtD
Zaleplon—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000491	CcSEcCtD
Zaleplon—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000491	CcSEcCtD
Zaleplon—Asthma—Methotrexate—systemic scleroderma	0.000321	0.000489	CcSEcCtD
Zaleplon—Decreased appetite—Lisinopril—systemic scleroderma	0.00032	0.000487	CcSEcCtD
Zaleplon—Eosinophilia—Methotrexate—systemic scleroderma	0.000318	0.000484	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000318	0.000484	CcSEcCtD
Zaleplon—Shock—Mycophenolate mofetil—systemic scleroderma	0.000317	0.000483	CcSEcCtD
Zaleplon—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000316	0.000481	CcSEcCtD
Zaleplon—Constipation—Lisinopril—systemic scleroderma	0.000315	0.000479	CcSEcCtD
Zaleplon—Pain—Lisinopril—systemic scleroderma	0.000315	0.000479	CcSEcCtD
Zaleplon—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000315	0.000479	CcSEcCtD
Zaleplon—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000477	CcSEcCtD
Zaleplon—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000312	0.000475	CcSEcCtD
Zaleplon—Nausea—Captopril—systemic scleroderma	0.000308	0.00047	CcSEcCtD
Zaleplon—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000307	0.000468	CcSEcCtD
Zaleplon—Asthenia—Leflunomide—systemic scleroderma	0.000307	0.000468	CcSEcCtD
Zaleplon—Hallucination—Prednisone—systemic scleroderma	0.000306	0.000466	CcSEcCtD
Zaleplon—Feeling abnormal—Lisinopril—systemic scleroderma	0.000303	0.000462	CcSEcCtD
Zaleplon—Pruritus—Leflunomide—systemic scleroderma	0.000303	0.000461	CcSEcCtD
Zaleplon—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000459	CcSEcCtD
Zaleplon—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000301	0.000458	CcSEcCtD
Zaleplon—Dysuria—Methotrexate—systemic scleroderma	0.0003	0.000457	CcSEcCtD
Zaleplon—Dizziness—Azathioprine—systemic scleroderma	0.0003	0.000457	CcSEcCtD
Zaleplon—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000296	0.00045	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000294	0.000447	CcSEcCtD
Zaleplon—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000293	0.000446	CcSEcCtD
Zaleplon—Asthenia—Mycophenolic acid—systemic scleroderma	0.000293	0.000446	CcSEcCtD
Zaleplon—Urticaria—Lisinopril—systemic scleroderma	0.000292	0.000445	CcSEcCtD
Zaleplon—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000291	0.000444	CcSEcCtD
Zaleplon—Abdominal pain—Lisinopril—systemic scleroderma	0.000291	0.000443	CcSEcCtD
Zaleplon—Body temperature increased—Lisinopril—systemic scleroderma	0.000291	0.000443	CcSEcCtD
Zaleplon—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000441	CcSEcCtD
Zaleplon—Pruritus—Mycophenolic acid—systemic scleroderma	0.000289	0.00044	CcSEcCtD
Zaleplon—Pneumonia—Methotrexate—systemic scleroderma	0.000288	0.000439	CcSEcCtD
Zaleplon—Eye disorder—Prednisone—systemic scleroderma	0.000287	0.000438	CcSEcCtD
Zaleplon—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000287	0.000438	CcSEcCtD
Zaleplon—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000436	CcSEcCtD
Zaleplon—Rash—Azathioprine—systemic scleroderma	0.000286	0.000435	CcSEcCtD
Zaleplon—Dermatitis—Azathioprine—systemic scleroderma	0.000286	0.000435	CcSEcCtD
Zaleplon—Depression—Methotrexate—systemic scleroderma	0.000285	0.000435	CcSEcCtD
Zaleplon—Headache—Azathioprine—systemic scleroderma	0.000284	0.000433	CcSEcCtD
Zaleplon—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000284	0.000432	CcSEcCtD
Zaleplon—Dizziness—Leflunomide—systemic scleroderma	0.000283	0.000431	CcSEcCtD
Zaleplon—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000427	CcSEcCtD
Zaleplon—Stomatitis—Methotrexate—systemic scleroderma	0.000279	0.000425	CcSEcCtD
Zaleplon—Conjunctivitis—Methotrexate—systemic scleroderma	0.000278	0.000424	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000424	CcSEcCtD
Zaleplon—Immune system disorder—Prednisone—systemic scleroderma	0.000278	0.000423	CcSEcCtD
Zaleplon—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00042	CcSEcCtD
Zaleplon—Pain—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00042	CcSEcCtD
Zaleplon—Sweating—Methotrexate—systemic scleroderma	0.000274	0.000418	CcSEcCtD
Zaleplon—Haematuria—Methotrexate—systemic scleroderma	0.000273	0.000416	CcSEcCtD
Zaleplon—Alopecia—Prednisone—systemic scleroderma	0.000272	0.000414	CcSEcCtD
Zaleplon—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000271	0.000412	CcSEcCtD
Zaleplon—Dizziness—Mycophenolic acid—systemic scleroderma	0.00027	0.000411	CcSEcCtD
Zaleplon—Epistaxis—Methotrexate—systemic scleroderma	0.00027	0.000411	CcSEcCtD
Zaleplon—Rash—Leflunomide—systemic scleroderma	0.00027	0.000411	CcSEcCtD
Zaleplon—Dermatitis—Leflunomide—systemic scleroderma	0.00027	0.000411	CcSEcCtD
Zaleplon—Mental disorder—Prednisone—systemic scleroderma	0.000269	0.00041	CcSEcCtD
Zaleplon—Nausea—Azathioprine—systemic scleroderma	0.000269	0.00041	CcSEcCtD
Zaleplon—Headache—Leflunomide—systemic scleroderma	0.000268	0.000408	CcSEcCtD
Zaleplon—Malnutrition—Prednisone—systemic scleroderma	0.000268	0.000408	CcSEcCtD
Zaleplon—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000266	0.000405	CcSEcCtD
Zaleplon—Asthenia—Lisinopril—systemic scleroderma	0.000264	0.000402	CcSEcCtD
Zaleplon—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000264	0.000401	CcSEcCtD
Zaleplon—Pruritus—Lisinopril—systemic scleroderma	0.00026	0.000396	CcSEcCtD
Zaleplon—Rash—Mycophenolic acid—systemic scleroderma	0.000257	0.000392	CcSEcCtD
Zaleplon—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000257	0.000392	CcSEcCtD
Zaleplon—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00039	CcSEcCtD
Zaleplon—Headache—Mycophenolic acid—systemic scleroderma	0.000256	0.00039	CcSEcCtD
Zaleplon—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000388	CcSEcCtD
Zaleplon—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000388	CcSEcCtD
Zaleplon—Nausea—Leflunomide—systemic scleroderma	0.000254	0.000387	CcSEcCtD
Zaleplon—Ill-defined disorder—Prednisone—systemic scleroderma	0.000248	0.000378	CcSEcCtD
Zaleplon—Visual impairment—Methotrexate—systemic scleroderma	0.000248	0.000377	CcSEcCtD
Zaleplon—Anaemia—Prednisone—systemic scleroderma	0.000247	0.000377	CcSEcCtD
Zaleplon—Agitation—Prednisone—systemic scleroderma	0.000246	0.000375	CcSEcCtD
Zaleplon—Angioedema—Prednisone—systemic scleroderma	0.000245	0.000373	CcSEcCtD
Zaleplon—Dizziness—Lisinopril—systemic scleroderma	0.000243	0.00037	CcSEcCtD
Zaleplon—Nausea—Mycophenolic acid—systemic scleroderma	0.000243	0.000369	CcSEcCtD
Zaleplon—Malaise—Prednisone—systemic scleroderma	0.000241	0.000368	CcSEcCtD
Zaleplon—Vertigo—Prednisone—systemic scleroderma	0.00024	0.000366	CcSEcCtD
Zaleplon—Eye disorder—Methotrexate—systemic scleroderma	0.00024	0.000366	CcSEcCtD
Zaleplon—Syncope—Prednisone—systemic scleroderma	0.00024	0.000366	CcSEcCtD
Zaleplon—Tinnitus—Methotrexate—systemic scleroderma	0.00024	0.000365	CcSEcCtD
Zaleplon—Loss of consciousness—Prednisone—systemic scleroderma	0.000235	0.000358	CcSEcCtD
Zaleplon—Immune system disorder—Methotrexate—systemic scleroderma	0.000232	0.000354	CcSEcCtD
Zaleplon—Rash—Lisinopril—systemic scleroderma	0.000232	0.000353	CcSEcCtD
Zaleplon—Dermatitis—Lisinopril—systemic scleroderma	0.000232	0.000353	CcSEcCtD
Zaleplon—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000352	CcSEcCtD
Zaleplon—Hypertension—Prednisone—systemic scleroderma	0.000231	0.000352	CcSEcCtD
Zaleplon—Chills—Methotrexate—systemic scleroderma	0.000231	0.000351	CcSEcCtD
Zaleplon—Headache—Lisinopril—systemic scleroderma	0.00023	0.000351	CcSEcCtD
Zaleplon—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000347	CcSEcCtD
Zaleplon—Myalgia—Prednisone—systemic scleroderma	0.000228	0.000347	CcSEcCtD
Zaleplon—Arthralgia—Prednisone—systemic scleroderma	0.000228	0.000347	CcSEcCtD
Zaleplon—Anxiety—Prednisone—systemic scleroderma	0.000227	0.000346	CcSEcCtD
Zaleplon—Alopecia—Methotrexate—systemic scleroderma	0.000227	0.000346	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000226	0.000345	CcSEcCtD
Zaleplon—Discomfort—Prednisone—systemic scleroderma	0.000225	0.000343	CcSEcCtD
Zaleplon—Mental disorder—Methotrexate—systemic scleroderma	0.000225	0.000343	CcSEcCtD
Zaleplon—Malnutrition—Methotrexate—systemic scleroderma	0.000224	0.000341	CcSEcCtD
Zaleplon—Dysgeusia—Methotrexate—systemic scleroderma	0.000219	0.000334	CcSEcCtD
Zaleplon—Nausea—Lisinopril—systemic scleroderma	0.000218	0.000333	CcSEcCtD
Zaleplon—Anaphylactic shock—Prednisone—systemic scleroderma	0.000218	0.000333	CcSEcCtD
Zaleplon—Oedema—Prednisone—systemic scleroderma	0.000218	0.000333	CcSEcCtD
Zaleplon—Back pain—Methotrexate—systemic scleroderma	0.000216	0.00033	CcSEcCtD
Zaleplon—Shock—Prednisone—systemic scleroderma	0.000215	0.000327	CcSEcCtD
Zaleplon—Nervous system disorder—Prednisone—systemic scleroderma	0.000214	0.000326	CcSEcCtD
Zaleplon—Tachycardia—Prednisone—systemic scleroderma	0.000213	0.000325	CcSEcCtD
Zaleplon—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000325	CcSEcCtD
Zaleplon—Skin disorder—Prednisone—systemic scleroderma	0.000212	0.000323	CcSEcCtD
Zaleplon—Hyperhidrosis—Prednisone—systemic scleroderma	0.000211	0.000322	CcSEcCtD
Zaleplon—Anorexia—Prednisone—systemic scleroderma	0.000208	0.000317	CcSEcCtD
Zaleplon—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000208	0.000316	CcSEcCtD
Zaleplon—Anaemia—Methotrexate—systemic scleroderma	0.000207	0.000315	CcSEcCtD
Zaleplon—Rash—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00031	CcSEcCtD
Zaleplon—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000203	0.000309	CcSEcCtD
Zaleplon—Headache—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000308	CcSEcCtD
Zaleplon—Malaise—Methotrexate—systemic scleroderma	0.000202	0.000307	CcSEcCtD
Zaleplon—Vertigo—Methotrexate—systemic scleroderma	0.000201	0.000306	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000199	0.000303	CcSEcCtD
Zaleplon—Insomnia—Prednisone—systemic scleroderma	0.000198	0.000301	CcSEcCtD
Zaleplon—Paraesthesia—Prednisone—systemic scleroderma	0.000196	0.000299	CcSEcCtD
Zaleplon—Dyspepsia—Prednisone—systemic scleroderma	0.000192	0.000293	CcSEcCtD
Zaleplon—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000292	CcSEcCtD
Zaleplon—Chest pain—Methotrexate—systemic scleroderma	0.00019	0.00029	CcSEcCtD
Zaleplon—Myalgia—Methotrexate—systemic scleroderma	0.00019	0.00029	CcSEcCtD
Zaleplon—Arthralgia—Methotrexate—systemic scleroderma	0.00019	0.00029	CcSEcCtD
Zaleplon—Decreased appetite—Prednisone—systemic scleroderma	0.00019	0.000289	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000189	0.000288	CcSEcCtD
Zaleplon—Discomfort—Methotrexate—systemic scleroderma	0.000188	0.000287	CcSEcCtD
Zaleplon—Constipation—Prednisone—systemic scleroderma	0.000187	0.000285	CcSEcCtD
Zaleplon—Confusional state—Methotrexate—systemic scleroderma	0.000184	0.00028	CcSEcCtD
Zaleplon—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000183	0.000278	CcSEcCtD
Zaleplon—Feeling abnormal—Prednisone—systemic scleroderma	0.00018	0.000274	CcSEcCtD
Zaleplon—Nervous system disorder—Methotrexate—systemic scleroderma	0.000179	0.000273	CcSEcCtD
Zaleplon—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000179	0.000272	CcSEcCtD
Zaleplon—Skin disorder—Methotrexate—systemic scleroderma	0.000177	0.00027	CcSEcCtD
Zaleplon—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000176	0.000269	CcSEcCtD
Zaleplon—Anorexia—Methotrexate—systemic scleroderma	0.000174	0.000265	CcSEcCtD
Zaleplon—Urticaria—Prednisone—systemic scleroderma	0.000174	0.000264	CcSEcCtD
Zaleplon—Abdominal pain—Prednisone—systemic scleroderma	0.000173	0.000263	CcSEcCtD
Zaleplon—Body temperature increased—Prednisone—systemic scleroderma	0.000173	0.000263	CcSEcCtD
Zaleplon—Hypotension—Methotrexate—systemic scleroderma	0.000171	0.00026	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000166	0.000253	CcSEcCtD
Zaleplon—Insomnia—Methotrexate—systemic scleroderma	0.000165	0.000252	CcSEcCtD
Zaleplon—Paraesthesia—Methotrexate—systemic scleroderma	0.000164	0.00025	CcSEcCtD
Zaleplon—Dyspnoea—Methotrexate—systemic scleroderma	0.000163	0.000248	CcSEcCtD
Zaleplon—Somnolence—Methotrexate—systemic scleroderma	0.000162	0.000247	CcSEcCtD
Zaleplon—Dyspepsia—Methotrexate—systemic scleroderma	0.000161	0.000245	CcSEcCtD
Zaleplon—Decreased appetite—Methotrexate—systemic scleroderma	0.000159	0.000242	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000158	0.00024	CcSEcCtD
Zaleplon—Asthenia—Prednisone—systemic scleroderma	0.000157	0.000239	CcSEcCtD
Zaleplon—Pain—Methotrexate—systemic scleroderma	0.000156	0.000238	CcSEcCtD
Zaleplon—Pruritus—Prednisone—systemic scleroderma	0.000155	0.000235	CcSEcCtD
Zaleplon—Feeling abnormal—Methotrexate—systemic scleroderma	0.00015	0.000229	CcSEcCtD
Zaleplon—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000149	0.000227	CcSEcCtD
Zaleplon—Urticaria—Methotrexate—systemic scleroderma	0.000145	0.000221	CcSEcCtD
Zaleplon—Dizziness—Prednisone—systemic scleroderma	0.000144	0.00022	CcSEcCtD
Zaleplon—Abdominal pain—Methotrexate—systemic scleroderma	0.000144	0.00022	CcSEcCtD
Zaleplon—Body temperature increased—Methotrexate—systemic scleroderma	0.000144	0.00022	CcSEcCtD
Zaleplon—Rash—Prednisone—systemic scleroderma	0.000138	0.00021	CcSEcCtD
Zaleplon—Dermatitis—Prednisone—systemic scleroderma	0.000138	0.00021	CcSEcCtD
Zaleplon—Headache—Prednisone—systemic scleroderma	0.000137	0.000208	CcSEcCtD
Zaleplon—Asthenia—Methotrexate—systemic scleroderma	0.000131	0.0002	CcSEcCtD
Zaleplon—Nausea—Prednisone—systemic scleroderma	0.00013	0.000198	CcSEcCtD
Zaleplon—Pruritus—Methotrexate—systemic scleroderma	0.000129	0.000197	CcSEcCtD
Zaleplon—Dizziness—Methotrexate—systemic scleroderma	0.000121	0.000184	CcSEcCtD
Zaleplon—Rash—Methotrexate—systemic scleroderma	0.000115	0.000175	CcSEcCtD
Zaleplon—Dermatitis—Methotrexate—systemic scleroderma	0.000115	0.000175	CcSEcCtD
Zaleplon—Headache—Methotrexate—systemic scleroderma	0.000114	0.000174	CcSEcCtD
Zaleplon—Nausea—Methotrexate—systemic scleroderma	0.000108	0.000165	CcSEcCtD
